Navigation Links
PCAS: 2008 Results
Date:2/18/2009

    LONGJUMEAU, France, February 18 /PRNewswire-FirstCall/ --
    - Sales Affected by the Economic Climate and Exceptional Events
    - Operating Profitability Has Resisted Well
    - Continued Reduction in Net Debt

    In millions of euros                  2008    2007

    Net sales                            168.4   185.3
    EBITDA*                               19.3    26.8
    EBITDA margin                         11.5%   14.5%
    Current operating income*              4.6    12.0
    Other operating income and expenses    1.0    (3.0).
    Financial results                     (5.4)   (5.6)
    Net income                            (0.9)    2.7
    Equity                                73.7    75.3
    Net debt                              62.4    70.1
    Gearing                               0.85    0.93
    Net asset per share                    5.7     5.8

* Including Research Tax Credit (CIR): 2.2 million euros in 2008 and 0.9 in 2007.

PCAS Group is listed on the Nyse Euronext compartiment C index, specialising in fine and speciality chemicals. It develops and manufactures high added-value molecules or molecules with a strong technological content for pharmacy, perfumery, cosmetics and industry.

The group's net sales were recorded at 168.4 million euros in 2008 as compared to 185.3 million in 2007, that is a 9.1% decline (-7.8% on a comparable basis).

The deterioration in the world's financial and economic climate was indeed felt:

    - In Pharmaceutical Synthesis with the postponement of a certain number
      of product development projects
    - In Fine Speciality Chemicals by the sudden drop in sales in
      the second half-year mainly in the Perfumery-Cosmetics
      markets

The Pharmaceutical Synthesis division's sales recorded a fall of 7.4% (8.1 million euros) in 2008, being predominantly linked to the exceptional invoicing at the beginning of 2007 of a product (phase 2) manufactured in 2006 and representing 4.2 million euros. It is also due to difficulties met by the Group's main customer in the supply of a raw material; difficulties that are being gradually resolved but which impacted sales in 2008 by 1.8 million euros. Lastly, the drop in value of the US Dollar, representing 1.5 million euros, also played a negative role.

As for the Fine Speciality Chemical division, it recorded a fall in sales of 11.6% (8.8 million euros), reflecting the conscious decision to stop manufacture of loss-making products or those considered to be insufficiently profitable at 1.1 million euro, as well as the impact of the unfavourable exchange rate (US Dollar), estimated at -0.9 million euros.

Operational profitability resisted well and debt reduction programme continued in a difficult climate, measures concerning cost reduction and margin improvements were continued to allow the Group to limit the decline in its operational profitability in 2008. The current EBITDA was recorded at 19.3 million euros as compared to 26.8 million euros in 2007. The Group's net debt was reduced to 62.4 million euros as compared to 70.1 million euros in 2007.

In 2008, other operating income and expenses mainly included the profit released by the Finnish subsidiary due to the sale of non-strategic financial assets. In 2007, it included the effects of the posting of the free share programme in particular, implemented in January 2007 (2.0 million euros), as well as restructuring costs (1.0 million euros).

Having taken into account the financial result and taxes, representing â¿¿ 5.4 million euros and -0.7 million euros in 2008 respectively, the PCAS Group's net income recorded a 0.9 million euro loss in 2008 as compared to a 2.7 million euro profit in 2007.

Forecast

Although the crisis in the world's financial and economic climate makes it particularly difficult to forecast, the Pharmaceutical Synthesis division should improve in 2009, whilst that of the Fine Speciality Chemical division should continue to be in retreat as compared to 2008, the two combined could however experience a slight increase.

In this context, the group plans to speed up and reinforce measures to adapt its production capacity to be more efficient and to return to its profitability objective as quickly as possible, and thus fully benefit from the recovery of the economic situation when it occurs.

It should be noted that the recent government decisions in terms of anticipated reimbursements of various fiscal accounts receivables (research tax credit and carry-back) will bring additional financing of almost 7 million euros, allowing the group to tackle the imposed changes whilst maintaining room for manoeuvre in an uncertain environment.

Moreover, PCAS will continue its policy of developing high added-value niche activities and increasing its international presence in buoyant markets. As such, from the beginning of first half-year 2009, PCAS should finalise two projects regarding North American development in association with local partners.

    Next Meeting:
    Shareholder's meeting on the 29th April 2009

    Contact:
    Philippe Delwasse
    Eric Moissenot
    +33(0)1-69-79-61-32

   http://www.pcas.com


'/>"/>
SOURCE PCAS
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
2. China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results
3. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
4. Escalon(R) Reports Second Quarter Fiscal 2009 Results
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
7. eResearchTechnology, Inc. to Announce Fourth Quarter and Full Year 2008 Results on February 26, 2009
8. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
9. Martek to Announce First Quarter 2009 Results
10. The Quantum Group Reports Year End Results for Fiscal Year 2008
11. Natural Alternatives International, Inc. Announces Fiscal 2009 Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... that have new attractive animation styles with unique displacement design elements," said Christina ... pre-animated lower third designs. Choose from a variety of design styles that include ...
(Date:12/4/2016)... PITTSBURGH, PA (PRWEB) , ... December 04, 2016 , ... ... not enough. One must brush properly to achieve optimal results. This important necessity inspired ... saw a need for a way to ensure that people break or avoid bad ...
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s ... help provide scholarship funds for area students and operating support to UNCF-member institutions, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  John Seng, founder of ... will succeed him as Chief Executive Officer following two consecutive years ... Wilson joined Spectrum as president in 2014 and assumed management of ... received public relations industry recognition as Healthcare Agency of the Year ... ...
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated to reach USD ... Research, Inc. Evolution of prenatal testing in the form of noninvasive tests ... diagnostic testing to determine the likelihood of fetal abnormality is expected to ... Continue Reading ... ...
Breaking Medicine Technology: